Please login to the form below

Not currently logged in
Email:
Password:

cHL

This page shows the latest cHL news and features for those working in and with pharma, biotech and healthcare.

Merck suspends two Keytruda trials after patient deaths

Merck suspends two Keytruda trials after patient deaths

Earlier this year Keytruda was approved for classical Hodgkin lymphoma (cHL) - its first non-solid tumour indication - and expanding into blood cancers is a key target for Merck.

Latest news

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    cHL), shortly after the FDA cleared the drug for the same blood cancer in the US. ... BMS' Opdivo (nivolumab) - which is already approved in the EU for cHL - was given the nod for the treatment for adults with squamous cell cancer of the head and neck

  • Keytruda claims first blood cancer OK from FDA Keytruda claims first blood cancer OK from FDA

    Merck &Co has won FDA clearance for its PD-1 inhibitor Keytruda in classical Hodgkin lymphoma (cHL), the first green light for the drug in a haematological cancer. ... The US regulator gave a conditional approval to Keytruda (pembrolizumab) for cHL

  • Opdivo gets green light for Hodgkin lymphoma in Europe Opdivo gets green light for Hodgkin lymphoma in Europe

    Less common than non-Hodgkin's lymphoma, cHL affects around 12, 200 people in the EU every year, often being diagnosed in early adulthood. ... BMS says the drug is still showing robust growth in other indications such as melanoma, renal cancer and cHL.

  • BMS wins early UK access for Opdivo in Hodgkin’s lymphoma BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

    The Medicines Healthcare Products and Regulatory Agency (MHRA) approved Opdivo for early access as a monotherapy for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) who have ... In a recent phase II trial, the

  • Roche gets first approval for PD-L1 inhibitor Tecentriq Roche gets first approval for PD-L1 inhibitor Tecentriq

    cell carcinoma and - just this week - classical Hodgkin's lymphoma (cHL). ... Opdivo's new approval in cHL is notable as it is the first for an immuno-oncology drug in haematological malignancies, showing the group can be useful outside the realm of

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics